The methotrexate polyglutamate assay supports the efficacy of methotrexate for severe inflammatory skin disease in children - 16/01/14
, Katherine H. Flanagan, MD c, Eric S. Armbrecht, PhD dAbstract |
Background |
The methotrexate (MTX) polyglutamate assay has been validated in adults with arthritis.
Objective |
We sought to assess clinical response rates and the value of the methotrexate polyglutamate assay in MTX-treated children with inflammatory skin diseases.
Methods |
In this retrospective review, 46 MTX-treated children with a diagnosis of atopic dermatitis, psoriasis, or psoriasis-eczema overlap were serially assessed with the methotrexate polyglutamate assay.
Results |
In all, 38 children (83%) achieved good to excellent response: 27 (59%) within 12 weeks and 11 (24%) after dose-adjustment. Good to excellent responses were highest for psoriasis/overlap: 15 of 16 (94%), compared with 23 of 30 (77%) with atopic dermatitis. Mean maximum polyglutamate levels were 31.5 nmol/L for responders versus 18.1 nmol/L for nonresponders (P = .035). This difference was also significant for the subset with atopic dermatitis, but not for those with psoriasis/overlap. After dose modification, late responders ultimately achieved a significantly higher mean maximum methotrexate polyglutamate assay (41.9 nmol/L) compared with nonresponders (P = .002).
Limitations |
Retrospective design and small sample size were limitations.
Conclusions |
MTX is an effective treatment for the majority of children with inflammatory skin diseases, but a subset requires dose modification to achieve good to excellent response. Methotrexate polyglutamate assay levels reflect response to treatment, but are most useful to support dose modification among children who fail to respond within 12 weeks.
Le texte complet de cet article est disponible en PDF.Key words : atopic dermatitis, methotrexate, methotrexate polyglutamate assay, overlap, pediatric/children, psoriasis
Abbreviations used : AD, MTX
Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
|
| Reprints not available from the authors. |
Vol 70 - N° 2
P. 252-256 - février 2014 Retour au numéro
Article précédent
- An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa
- Kieron S. Leslie, Shivani V. Tripathi, Tien V. Nguyen, Mariela Pauli, Michael D. Rosenblum
- Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian Psocare Registry
- Stefano Piaserico, Simone Cazzaniga, Sergio Chimenti, Alberto Giannetti, Mara Maccarone, Mauro Picardo, Andrea Peserico, Luigi Naldi, Psocare Study Group *
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?